Vincerx Pharma Inc (NASDAQ:VINC) has a beta value of 1.07 and has seen 7.36 million shares traded in the last trading session. The company, currently valued at $3.79M, closed the last trade at $0.10 per share which meant it lost -$0.03 on the day or -19.44% during that session. The VINC stock price is -9270.0% off its 52-week high price of $9.37 and 0.0% above the 52-week low of $0.10. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.7 million shares traded. The 3-month trading volume is 7.60 million shares.
The consensus among analysts is that Vincerx Pharma Inc (VINC) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
Vincerx Pharma Inc (NASDAQ:VINC) trade information
Sporting -19.44% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the VINC stock price touched $0.10 or saw a rise of 36.06%. Year-to-date, Vincerx Pharma Inc shares have moved -60.43%, while the 5-day performance has seen it change -25.77%. Over the past 30 days, the shares of Vincerx Pharma Inc (NASDAQ:VINC) have changed -49.78%. Short interest in the company has seen 4.71 million shares shorted with days to cover at 0.25.
Wall Street analysts have a consensus price target for the stock at $2, which means that the shares’ value could jump 95.0% from current levels. The projected low price target is $2.0 while the price target rests at a high of $2.0. In that case, then, we find that the current price level is -1900.0% off the targeted high while a plunge would see the stock gain -1900.0% from current levels.
Vincerx Pharma Inc (VINC) estimates and forecasts
Figures show that Vincerx Pharma Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -84.03% over the past 6 months, with this year growth rate of 60.85%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -283.70% over the past 5 years.
VINC Dividends
Vincerx Pharma Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Vincerx Pharma Inc (NASDAQ:VINC)’s Major holders
Insiders own 12.07% of the company shares, while shares held by institutions stand at 18.63% with a share float percentage of 21.19%. Investors are also buoyed by the number of investors in a company, with Vincerx Pharma Inc having a total of 32.0 institutions that hold shares in the company. The top two institutional holders are PROSIGHT MANAGEMENT, LP with over 2.49 million shares worth more than $2.02 million. As of 2024-06-30, PROSIGHT MANAGEMENT, LP held 11.6281% of shares outstanding.
The other major institutional holder is ARMISTICE CAPITAL, LLC, with the holding of over 1.99 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.61 million and represent 9.2897% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 1.01% shares in the company for having 341.07 shares of worth $35471.0 while later fund manager owns 280.42 shares of worth $29163.0 as of Sep 30, 2024 , which makes it owner of about 0.83% of company’s outstanding stock.
